Literature DB >> 26787610

Venous thromboembolism occurring during adolescence.

Tina Biss1, Raza Alikhan2, Jeanette Payne3, Jayanthi Alamelu4, Michael Williams5, Michael Richards6, Mary Mathias7, Oliver Tunstall8, Elizabeth Chalmers9.   

Abstract

OBJECTIVE: Risk assessment for venous thromboembolism (VTE) and thromboprophylaxis in those with risk factors is established in adult practice. Evidence to support efficacy and safety of this approach in adolescents is lacking. We aimed to describe thrombotic risk factors and to determine the proportion of potentially preventable events in a retrospective cohort study of adolescents with VTE. DESIGN, SETTING AND PATIENTS: Data were collected between 2008 and 2014 from eight tertiary UK centres. Qualifying events were radiologically confirmed VTE in subjects aged 12-17 years. Central venous line-related upper venous system events were excluded.
RESULTS: 76 cases were identified, 41 males, median age 15 years. Frequent risk factors were: reduced mobility, 45%; thrombophilia, 24%; malignancy, 20%; surgery, 18%; combined oral contraceptive pill, 12%; congenital venous anomaly, 5%. 28 (37%) had no significant underlying diagnosis and no provoking event/hospitalisation, presenting as outpatients with VTE which was considered 'unpreventable'. Of 48 where there had been opportunity for risk assessment, chemical thromboprophylaxis was not indicated in 26 and was contraindicated in 8. 14/76 (18%) had an indication to consider thromboprophylaxis and no contraindication. Of these, four had cerebral palsy, five malignancy and two inflammatory bowel disease. All had reduced mobility with recent surgery in eight. Four received chemical thromboprophylaxis prior to presentation.
CONCLUSIONS: Among a cohort of adolescents with VTE, a small proportion (13%) had an indication to consider chemical thromboprophylaxis but did not receive it. VTE risk assessment and prevention should focus on adolescents with immobility or surgery, particularly in those with malignancy. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Entities:  

Keywords:  Adolescent Health; Haematology; Thromboprophylaxis; Thrombosis

Mesh:

Substances:

Year:  2016        PMID: 26787610     DOI: 10.1136/archdischild-2015-309875

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  4 in total

Review 1.  Venous thromboembolism in paediatrics.

Authors:  S Jinks; A Arana
Journal:  BJA Educ       Date:  2019-07-10

2.  International pediatric thrombosis network to advance pediatric thrombosis research: Communication from the ISTH SSC subcommittee on pediatric and neonatal thrombosis and hemostasis.

Authors:  C Heleen van Ommen; Manuela Albisetti; Mohir Bhatt; Marianne Bonduel; Brian Branchford; Elizabeth Chalmers; Anthony Chan; Neil A Goldenberg; Susanne Holzhauer; Paul Monagle; Ulrike Nowak-Göttl; Shoshana Revel-Vilk; Gabriela Sciuccatie; Nongnuch Sirachainan; Christoph Male
Journal:  J Thromb Haemost       Date:  2021-04       Impact factor: 5.824

3.  Hip Replacement Surgery in 14-Year-Old Girl with Factor V Deficiency: Haemostatic Treatment and Thromboprophylaxis.

Authors:  María Eva Mingot-Castellano; Josefina Pérez-Núñez; Lourdes Baeza-Montañez
Journal:  Case Rep Hematol       Date:  2016-10-30

4.  Phase 3, single-arm, multicenter study of dabigatran etexilate for secondary prevention of venous thromboembolism in children: Rationale and design.

Authors:  Matteo Luciani; Manuela Albisetti; Branislav Biss; Lisa Bomgaars; Martina Brueckmann; Elizabeth Chalmers; Savion Gropper; Jacqueline M L Halton; Ruth Harper; Fenglei Huang; Ivan Manastirski; Lesley G Mitchell; Igor Tartakovsky; Bushi Wang; Leonardo R Brandão
Journal:  Res Pract Thromb Haemost       Date:  2018-04-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.